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Abstract: The microbiota in the human intestine play an important function in human health 
and  disease.  Gastrointestinal  infections  by  foodborne  pathogens  are  a  main  cause  of 
morbidity and mortality worldwide. Such infections can be caused by contaminated foods or 
other sources which come in contact with human intestinal epithelial cells. In recent years, 
probiotics have been recommended as alternative biotherapeutic agents against intestinal 
pathogenic infections. Two genera of probiotics, Lactobacillus and Bifidobacterium, are 
commercially valuable applications, several forms of which are available as capsules or in 
functional food products such as yogurt, fermented juices and sausages. Probiotics protect 
against  gastrointestinal  pathogenic  infection  via  several  mechanisms.  These  include 
production  of  antimicrobial  substances,  competition  for  nutrient  substrates,  competitive 
exclusion,  enhancement  of  intestinal  barrier  function,  and  immunomodulation.  Probiotic 
bacteria  have  been  documented  as  being  effective  in  biotherapeutic  applications  against 
gastrointestinal pathogens, e.g. Helicobacter pylori, Salmonella, Escherichia coli, Listeria 
monocytogenes,  and rotaviruses. This alternative therapeutic application of probiotics to 
protect against gastrointestinal pathogenic infections may be of great importance for future 
medicinal use. 
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INTRODUCTION 
  
The human gastrointestinal tract harbours a complex and diverse ecosystem of microbiota or 
commensal microflora. It has been assumed that these microbiota range from 10
12 to 10
14 CFU/g of 
the luminal content [1]. There are in our body more than 2,000 different species, the majority of  
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which reside in the intestines [2]. Different communities of aerobic, facultative and anaerobic bacteria 
all  constitute  the  gastrointestinal  microbiota.  The  proportion  of  anaerobic  bacteria  gradually 
increases on going from proximal to distal areas; 99% of the inhabitants in the large intestine are 
anaerobes [3]. The diversity of microbiota species residing in the gastrointestinal tract is dependent 
upon the host’s age, diet and health status [4]. Srikanth and McCormick [5] suggested that the 
intestinal  mucosa  may  play  a  central  role  in  host-microbiota-pathogen  interactions.  The  human 
intestine is also an area which supports the energy metabolism and the immune function. Human 
microbiota may also play a critical role in disease and human health as suggested by Guarner and 
Malagelada [6] and Thirabunyanon et al [7].  Some cancers such as gastric cancer [8] and colon 
cancer  [9]  are  also  associated  with  the  human  microbiota  and  intestinal  pathogenic  infection. 
Probiotics  have  been  promoted  as  new  alternative  biotherapeutic  agents  for  human  intestinal 
diseases. This report summarises the interactions between the host, microbiota and pathogens. It 
includes the use of probiotic bacteria as biotherapeutic agents in protection against, and treatment of, 
gastrointestinal infections.         
 
FUNCTIONS OF MICROBIOTA IN THE GASTROINTESTINAL TRACT 
 
The functions of microbiota in the human intestine consist of several main activities including 
metabolism, nutrition and disease protection (Table 1). Recent investigations using new techniques 
of molecular taxonomy have shed light on the composition, dynamics and ecology of the microbiota. 
Investigation of the diversity of human microbiota has revealed that this microbiota genome is at 
least 100 times larger than the human genome [10]. There are several types of microbial population 
in  the  human  intestine  such  as  Lactobacillus  spp.,  Bifidobacterium  spp.,  Escherichia  coli  and 
Bacillus  spp.  (Table  1).  Three  groups
__aerobic,  facultative  and  anaerobic bacteria
__are indicated. 
However, the most abundant in the bacterial community are anaerobes, most of which (about 60-
90%) are expressed in two divisions: the Bacteroidetes and the Firmicutes [11]. Eukaryotic fungi are 
also identified among the microorganisms inhabiting the intestinal tract [12].  
The functions of intestinal microbiota may include diverse actions in the gastrointestinal tract 
including production of metabolites, nutritional fermentation and participation in the host’s immune 
defense system. One role of human microbiota may involve maintaining nutritional homeostasis in the 
intestine.  Nicholson  and  Wilson  [13]  suggested  that  several  compounds  produced  from  the 
microbiota co-metabolise nutrients with the host enzymes such as cytochrome P450 and conjugating 
enzymes in the liver. Ultimately these digested nutrients are absorbed by intestinal epithelial cells. 
The microbiota in the gastrointestinal tract may also produce or enrich metabolites such as glycans, 
amino acids, xenobiotics, vitamin K, folate and short-chain fatty acids (SCFA) [4, 10]. Starches are 
not easily digested by the human digestive system; however, the process is assisted by microbial 
fermentation. Turnbaugh et al. [14] indicated that the microbiota most able to produce SCFA are 
Firmicutes such as Clostridium spp. and Bifidobacterium spp. The primary metabolic end products 
of such fermentation are organic acids including SCFA such as butyrate, succinate and propionate [4, 
15]. The functional roles of SCFA in colonic physiology may result in control of proliferation and 
differentiation of the intestinal epithelial cells [5, 16].  
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Table 1. Microbiota in the human gastrointestinal tract and their occurrence and/or possible functions  
 
      Microbiota          Occurrence and/or possible functions  Reference 
Bacteroides spp. 
Lactobacillus spp. 
Bifidobacterium spp. 
Streptococcus spp. 
Escherichia coli 
Clostridium spp. 
 
These bacteria originate from the birth canal and 
commence immediately after birth to colonise the 
gut;  later  they  remain  predominant  in  the 
gastrointestinal tract.   
 
[3] 
 
Enterococcus faecalis 
 
Normally  prevalent  in  healthy  humans,  but  can 
cause infection under certain conditions.  
 
[5] 
Clostridium spp. 
Bifidobacterium spp. 
 
 
High  metabolic  capacity,  producing  short-chain 
fatty acids (SCFA) within the lumen of the human 
gastrointestinal tract. 
 
[14] 
 
Pediococcus acidilactici 
MM33 
 
 
The  first  human  bacteriocin  (pediocin)-producing 
strain which was found to be bactericidal against 
Listeria monocytogenes.  
 
[34] 
 
Lactobacillus johnsonii 
NCC 533 
 
The  original  strain  isolated  from  the  human 
intestine  that  produces hydrogen peroxide and is 
effective in killing Salmonella typhimurium.       
 
[36] 
 
Lactobacillus rhamnosus 
IMC 501 
Lactobacillus paracasei 
IMC 502 
 
These  antimicrobial  strains  could  be  used  as 
health-promoting  bacteria  against  harmful 
pathogens in humans.   
 
[37] 
 
Lactobacillus plantarum 
CS23 
 
This  strain  induces  potentially  significant 
immunomodulatory activity in humans.    
 
[38] 
 
 
FUNCTION OF EPITHELIAL CELLS IN  GASTROINTESTINAL TRACT 
  
Protection of the host against intestinal pathogens is effected by the physical and chemical 
barriers of the gastrointestinal epithelium (Figure 1), which primarily consists of absorptive epithelial 
cells (enterocytes) [17]. Madara et al. [18] suggested that the human gut epithelium has a surface 
area  of  300-400  m
2,  comparable  to  the  size  of  a  tennis  court.  Epithelial  cells  lining  the 
gastrointestinal  tract  constitute  areas  where  contact  is  made  between  host  and  microbes.  The 
structures of the apical surfaces of the epithelial cells are specialised and include microvilli, rigid 
intercellular  junctions,  and  areas  for  ion  secretion  and  mucus  production  [11].  Moreover,  the 
microvillous tips of the epithelial cells have a surface coating of a mucous layer [17]. The intestinal 
epithelium   also  consists  of   several  other  cell  types  such  as  goblet  cells,  microfold  (M)  cells,   
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enteroendocrine cells, and Paneth cells. The intercellular junctional complexes are comprised of tight 
junctions,  adherens  junctions  and  desmosomes.  The  roles  of  these  junctional  complexes  are  to 
maintain the integrity of the epithelial barrier and to act as a physical barrier to prevent unwanted 
bacteria from entering the host [5].  
The goblet cells secrete mucus in order to produce a mucous layer overlying the intestinal 
epithelium  (Figure  1).  This  serves  as  a  physical  blockade  protecting  against  harmful  pathogens, 
which has been demonstrated with Shigella flexneri [19] and Yersinia enterocolitica [20]. The M 
cells  differ  from  normal  epithelial  cells  in  that  they  lack  microvilli  on  their  apical  surfaces.  The 
primary  roles  of  these  M  cells  are  in  the  transport  of  antigens,  particles,  macromolecules  and 
microorganisms  in  the  lumen  through  to  the  Peyer’s  patch  and  lymphoid  tissue  [21-22]. 
Enteroendocrine  cells  are  hormone-secreting  cells  that  sense  the  luminal  environment  and 
immediately react to secrete the correct peptide hormones such as cholecystokinin  and  secretin  [5, 
23]. The Paneth cells are another type of cells responsible for protection of the intestinal epithelium 
against  pathogenic  bacteria  (Figure  1).  They  secrete  certain  antimicrobial  peptides,  e.g.  alpha-
defensinsand  cathelicidins.  Paneth  cells  also  produce  several  antimicrobial  molecules  including 
lysozyme, phospholipase A2 and angiogenin-4 [23]. 
One important function of the intestinal epithelium is to create a surface where the host can 
sense  the  microbial  microenvironment  and  generate  protective  responses  against  pathogens  by 
producing  an  array  of  signalling  molecules,  e.g.  chemokines  and  cytokines.  These  molecules 
stimulate the recruitment of leukocytes to initiate an early inflammatory response [5]. The host’s 
immune  response  is  expressed  upon  pathogenic  infection;  the  specific  recognition  of  molecular 
structures is determined by pathogen-associated molecular patterns. It has been proposed that the 
epithelial cells sense the microenvironment within the gut via pattern recognition receptors (PRR) 
including Toll-like receptors (TLRs) and nucleotide-binding oligimerisation domain (NOD) protein 
[24-25].                   
 
INFECTION PROCESSES OF GASTROINTESTINAL PATHOGENS 
 
Enteric diseases are caused by several pathogens, notably Salmonella spp., Escherichia coli, 
Shigella,  Yersinia  and  various  other  foodborne  pathogenic  strains  such  as  Bacillus  cereus, 
Staphylococcus aureus, Listeria monocytogenes and Vibrio cholerae. Salmonella is known to be 
implicated in human foodborne illnesses and often enters the food supply via contamination of food 
products such as poultry, pork, beef, dairy products and nuts, especially peanut and pistachio [26]. 
Other strains of foodborne pathogens also typically contaminate human foods.  
There  are  two  steps  in  gastrointestinal  pathogenic  infection.  At  the  initial  stage  of  the 
infection  process,  the  pathogens  attach  themselves  to  the  surfaces  of  intestinal  epithelial  cell 
structures consisting of glycoproteins and glycolipids, which serve as receptors for bacterial adhesion 
[27-28].    Salmonella  spp.  entering  via  the  faecal/oral  route  can  survive  in  and  colonise  the 
gastrointestinal tract. Adhesion to the epithelial cells is mediated by fimbriae or pili present on the 
bacterial cell surface [29]. During this entry step, bacterial pathogens can pass through the epithelial 
barrier, triggering a proinflammatory response [30]. During the second step of the infection process, 
direct cytotoxic injury, intracellular migration, and disruption of the epithelial tight junctions lead to 
mucosal infection and systemic spread of the disease [31-32].  
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Figure 1.  Functions of microbiota and epithelial cells in the lumen of human gastrointestinal tract. 
Intestinal  microbiota  are  comprised  of  diverse  groups  (shown  in  different  colours),  i.e.  aerobic, 
facultative and anaerobic bacteria, with different morphology such as rod and coccus. The intestinal 
epithelium consists of several cell types: intestinal epithelial, goblet, microfold, enteroendocrine, and 
Paneth cells. A mucous layer (brown) is a natural secretion produced by goblet cells and serves as a 
physical  blockade  protecting  against  pathogenic  infection.  Defensins  (small  black  granules)  are 
antimicrobial peptides secreted by Paneth cells against gastrointestinal pathogens.    
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THE CONCEPT OF PROBIOTICS  
 
A probiotic is ‘a live microbial food ingredient that is beneficial to health’ [33]. Probiotics 
have recently received special attention on their application as an alternative approach to prevention 
of and therapy for several human gastrointestinal diseases [34-35]. Most of these potential probiotics 
are of human origin and are isolated from microbiota in the human gastrointestinal tract [34, 36-38]. 
Other sources are several human food products [39-41], which were also reported in our previous 
study of natural bacteria isolated from fermented milk products [7]. Recently, probiotic bacterial 
formulations have been developed for consumers in the forms of dietary supplements, yogurts, drinks 
and capsules.  Two genera,  Lactobacillus and Bifidobacterium, have been found to be excellent 
potential sources of bacterial probiotics.  In addition, some species of Enterococcus, Streptococcus 
and Bacillus have also been suggested to have probiotic properties [7, 42-43].  
Many criteria must be met to establish that a new bacteria strain is probiotic. These include 
non-pathogenicity, ability to inhibit the growth of pathogenic strains, tolerance for acid and bile salt 
conditions of the gastrointestinal tract, and ability to adhere to intestinal epithelial cells [7, 33, 44]. In 
vivo testing must be conducted in order to evaluate the probiotic activity in the body. If both in vitro 
and in vivo studies are successful, the probiotic bacteria can be used as a biotherapeutic agent in 
humans.     
 
MECHANISMS  OF  PROBIOTIC  ACTIONS  AGAINST  GASTROINTESTINAL  PATHOGENIC 
INFECTION 
 
Since  the  past  decade  probiotic  biotherapeutic  agents  have  increasingly  been  applied  for 
prevention  of  and  therapy  for  intestinal  pathogenic  infection.  Consumption  of  probiotics  may 
modulate  the  microbiota  in  the  gastrointestinal  tract  and  change  their metabolic properties [45]. 
Many  mechanisms  have  recently  been  postulated  for  these  probiotic  activities  in  the  human 
gastrointestinal tract (Figure 2) [46-50].  
 
Production of Antimicrobial Substances 
 
One  action  of  probiotics  is  that  they  can  produce  antimicrobial  substances  as  direct 
antagonists  against  intestinal  pathogens.  Probiotics  may  exert  their  effective  antagonistic  activity 
alone or synergistically. Recent studies have indicated that the antagonistic activities against intestinal 
pathogens are produced by antimicrobial substances from several probiotic strains [7, 37-38]. These 
antimicrobial substances were found to range in size from small molecules to bioactive peptides. 
Bacteriocins  are  important  ribosomally  synthesised  antimicrobial  peptides  which  have  been 
documented as possessing a good functional therapeutic activity against gastrointestinal pathogenic 
infection. These bacteriocins have been categorised into four classes: class-I bacteriocins are small 
peptides (which are also classified as lantibiotics) such as nisin; class-II bacteriocins are small, heat-
stable  peptides  such  as  pediocin;  class-III  bacteriocins  are  large,  heat-labile  proteins  such  as 
helveticin  J;  and  class-IV  bacteriocins  are  complex  bacteriocins  [3,  51-52].  Millette  et  al.  [34] 
indicated that pediocin, the bacteriocin secreted by Pediococcus acidilactici MM33 isolated from the 
human gut, was bactericidal against Listeria monocytogenes. Reuterin, an antimicrobial compound 
produced  by  some  strains  of  Lactobacillus  reuteri,  may  act  as  an  antagonist  against  enteric  
pathogens   [35, 53].   A   study   by   Pridmore   et   al.  [36]   showed   that   the   human   intestinal   
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Figure  2.  Schematic  illustration  of  postulated  mechanisms  of  probiotic  bacterial  actions  against 
gastrointestinal pathogenic infection: (1) production of antimicrobial substances; (2) competition for 
nutritional substrates; (3) competitive exclusion; (4) enhancement of intestinal barrier function; and 
(5) immunomodulation.           
 
 
    
  
Maejo Int. J. Sci. Technol.  2011, 5, 108-128   
 
 
115
probiotic strain of L. johnsonii NCC533 (La1) can produce hydrogen peroxide that is effective in 
killing Salmonella typhimurium.  
Other  metabolites  from  probiotics  are  potential  antimicrobial  substances  that  can  protect 
against  intestinal  pathogenic  infection.  It  has  been  found  that  five  strains  of  Pediococcus  spp. 
produce  several  factors  that  inhibit  the  growth  of  Listeria  monocytogenes,  notably  hydrogen 
peroxide, lactic acid, exopolysaccharides, and proteolytic activity [39]. Probiotics which can produce 
metabolites such as acetic and lactic acids may lower the pH in the intestine. This lowering of pH 
results  in  inappropriate  environmental  conditions  for  pathogenic  growth.  An  in  vitro  study  by 
Ridwan  et  al.  [54]  showed  that  the  antimicrobial  activity  of  a  multi-species  probiotic  product 
(Ecologic  641)  may  be  exerted  by  the  production  of  organic  acids.  Likewise,  a  biosurfactant 
produced from Lactobacillus paracasei was shown to have bactericidal activity that inhibited the 
growth of several pathogens [55]. 
 
Competition for Nutritional Substrates 
 
The enteric probiotic population in the gastrointestinal tract may increase after consuming 
nutrients. Thus, competition for nutritional substrates amongst probiotics, intestinal pathogens and 
microbiota may occur. Hojo et al. [56] suggested that Bifidobacterium adolescentis S2-1 can better 
utilise vitamin K and inhibit the growth of Porphyromonas gingivalis by competing for the growth 
factor. In an animal model of germ-free mice colonised with human baby microbiota, the diverse 
metabolic profiles have been investigated after exposure to a probiotic strain of either Lactobacillus 
paracasei  or  Lactobacillus  rhamnosus.  These  probiotic  treatments  may  alter  a  diverse  range  of 
pathways  which  include  the  metabolism  of  amino  acid,  methylamines and SCFA [57]. Similarly, 
Stanton et al. [58] produced biogenic metabolites such as vitamins, fatty acids and bioactive peptides 
which  were  marked  through  applying  probiotics  in  fermented  functional  foods.  The  biogenic 
metabolites may act as a growth substrate for selected compounds with different probiotics, intestinal 
pathogens or microbiota.       
 
Competitive Exclusion 
 
Probiotics can eliminate pathogens at the adhesion and infection site of epithelial cells in the 
human  intestine  by  competitive  exclusion.  Infection  begins  with  the  binding  of  the  pathogen  to 
intestinal epithelial cells through the interaction between bacterial lectins and carbohydrate moieties 
of glycoconjugate receptor molecules on the intestinal epithelial cell surface [47]. Mukai et al. [59] 
suggested that the binding ability of Bifidobacterium bifidum and Lactobacillus reuteri to intestinal 
glycolipids  may  play  an  important  role  in  their  ability  to  adhere  to  the  epithelial  surface  of  the 
intestine. Competition study by Ramiah et al. [60] indicated that Lactobacillus plantarum 423 is able 
to  colonise  intestinal  epithelial  cells,  thus  preventing  the  adhesion  of  pathogenic  Clostridium 
sporogenes and Enterococcus faecalis. These findings were similar to the author’s unpublished data 
which  indicated  that a  novel  probiotic  strain  of  Bacillus  subtilis  NC11 has a protective activity 
against Salmonella enteritidis infection of intestinal epithelial cells. Thus, probiotic actions against 
pathogenic  infection  can  be  through  competitive  adhesion  and/or  blocking  of  the  penetration  of 
pathogens at the infection site of intestinal epithelium cells by competing for the glycoconjugate 
receptors.   
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Enhancement of Intestinal Barrier Function 
 
The  pathophysiology  of  intestinal  pathogenic  infection  displays  a  disruption  of  epithelial 
barrier function and a loss of tight junction formation in the intestinal epithelium cells [61]. These 
phenomena can increase the pathogenic or enterotoxic permeability of the mucosa wall. Probiotics 
have  been  promoted  for  their  enhancement  of  intestinal  barrier  function  by  impeding  the 
translocation and attachment of pathogenic bacteria to the intestinal epithelium [62]. Khailova et al. 
[63] showed in a rat model that administration of Bifidobacterium bifidum may have a protective 
effect through regulation of the main components of the mucous layer and improvement of intestinal 
integrity. Similarly, Mennigen et al.[64] suggested that the probiotic mixture VSL#3 can protect the 
epithelial barrier in a mouse model of acute colitis by maintaining tight junction protein expression 
and preventing the increase of apoptotic ratio.  
 
Immunomodulation 
 
The role of intestinal epithelial cells is associated with immunomodulation through complex 
interactions  between  immune  cells  and  probiotics,  triggering  a  cascade  of  appropriate  innate  or 
adaptive  immune  defense  responses  [47,  65].  The  production  of  pro-inflammatory  or  anti-
inflammatory  cytokines  by  human  peripheral  blood  mononuclear  cells  is  challenged  with 
Lactobacillus plantarum L2. It was found that this bacterium can induce interleukin (IL)-10 but only 
low levels of the pro-inflammatory cytokines TNF-alpha, IFN-gamma and IL-12. During an in vivo 
study, a significant increase in CD19-positive cells in the ileum was found after a daily feeding of L. 
plantarum L2 in rats [66]. Amit-Romach et al. [67] indicated that administration of the probiotic 
strain Lactobacillus GG and a mixture of Streptococcus thermophilus, Lactobacillus acidophilus 
and Bifidobacterium lactis in rats may reduce the expression of pro-inflammatory cytokines TNF-
alpha and IL-6. Martínez-Cañavate et al. [68] suggested that consumption of probiotic products by 
children may result in enhanced innate immunity through a significant increase in natural killer cells 
and other specific immune factors that may improve their health status.                           
 
PROBIOTICS  AS  BIOTHERAPEUTIC  AGENTS  IN  GASTROINTESTINAL  PATHOGENIC 
INFECTIONS 
 
Enteric pathogenic infections are a main cause of morbidity and mortality worldwide. It has 
been recorded that severe diarrhea and dehydration caused the deaths of 1,575,000 children under 
the age of five in 2006
__15% of the 10.5 million deaths per year of children in this age group [69]. 
The  enteric  pathogens,  notably  Helicobacter  pylori,  Salmonella  enteritidis,  S.  typhimurium, 
Escherichia  coli,  Bacillus  cereus,  Listeria  monocytogenes,  Clostridium  difficile,  Campylobacter 
jejuni and Vibrio cholerae, cause a variety of human diseases including gastroenteritis, peptic ulcer 
and diarrhea. These pathogens are also associated with gastric [8] and colon cancers [9]. Probiotics 
have  been  applied  as  alternative  and  biotherapeutic  agents  for  prevention  of  and  therapy  for 
gastrointestinal pathogenic infections as described below.    
   
 Helicobacter pylori 
  
Pathogenic infection by H. pylori can lead to chronic gastritis and peptic ulcer and increase 
the risk of gastric cancer [70]. H. pylori infection is currently treated with a proton pump inhibitor  
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combined with clarithromycin and amoxicillin or metronidazole [71]. Although the use of antibiotics 
for treatment is efficient, it is expensive and has many side effects including stimulation of antibiotic 
resistance in intestinal pathogens [72]. As a result, alternative application of probiotics for prevention 
of and therapy for H. pylori has been investigated. Pathogenic H. pylori are known to produce 
urease, which can hydrolyse urea to ammonium species, resulting in elevated pH in the stomach and 
promoting  adhesion  of  microorganisms  [73].  Thirabunyanon  et  al.  [7]  found  that  the  potential 
probiotics,  Enterococcus  faecium  RM11  and  Lactobacillus  fermentum  RM28,  isolated  from 
fermented dairy products could inhibit the growth of pathogenic H. pylori. In an investigation, 14 
patients infected with H. pylori received milk containing the probiotic Lactobacillus casei Shirota 
strain continually for 6 weeks. The results showed that urease activity declined in 64% of the patients 
who consumed the fermented milk, as compared with 33% for the control group [74]. Similar results 
were  obtained  by  Myllyluoma  et  al. [75],  who  concluded  that  decreasing  urease  and  gastrin-17 
activities  were  found  in  H.  pylori-infected  patients  who  consumed  a  probiotic  combination  of 
Lactobacillus  rhamnosus  GG,  L.  rhamnosus  LC705,  Propionibacterium  freudenreichii  JS  and 
Bifidobacterium lactis Bb12 for 8 weeks.    
The  suppression  of  H.  pylori  binding  to  the  glycolipid  receptors  by  the  probiotic 
Lactobacillus  reuteri  has  been  reported  [76].  Lin  et  al.  [77]  proposed  that  lactic  acid  bacteria 
isolated from commercial food products can inhibit H. pylori infection at the adhesion sites of human 
gastric  epithelial  AGS  cells.  Sgouras  et  al.  found  that  Lactobacillus    casei  Shirota  was  highly 
effective in reducing H. pylori colonisation in the antrum and body mucosa in a mouse model [78] 
while  Lactobacillus  gasseri  OLL2716  was  shown  to  be  effective  against  H.  pylori  infection  in 
children [79]. Similarly, Wang et al. [80] indicated that regular consumption of yogurt containing 
Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12 may be effective in inhibiting H. 
pylori infection in humans. The outcome of using two combined probiotic strains of Bacillus subtilis 
and Streptococcus faecium for H. pylori eradication in patients were observed. These actions of the 
probiotic group were found to have a higher eradication rate (83.5%) than that of the control group 
(73.3%) [81].  
   
 Salmonella spp. 
  
Salmonella is a major foodborne pathogen normally found in many food products. It causes 
many  human  diseases  such  as  gastroenteritis,  enteric  fever,  bacteremia,  focal  infections  and 
enterocolitis.  Human  salmonellosis  has  become  an  important  international  public  health  and 
economic issue [82-84]. Continual use of antimicrobial agents for treatment of salmonellosis may 
result in the emergence of antibiotic-resistant strains of Salmonella. This multi-drug resistance has 
caused great public health concern [85-86].  
The study of Thirabunyanon et al. [7] showed that lactic acid bacteria isolated from dairy 
products suppress the growth of Salmonella typhimurium and S. enteritidis [7]. Maragkoudakis et 
al. [87] observed that two food-derived probiotics, Enterococcus faecium PCD71 and Lactobacillus 
fermentum ACA-DC179, when co-cultured in raw chicken meat, could protect it against Salmonella 
enteritidis contamination by inhibiting its growth. A protective role of Lactobacillus acidophilus 
Bar13,  L.  plantarum  Bar10,  Bifidobacterium  longum  Bar33  and  B.  lactis  Bar30  strains  against 
Salmonella  typhimurium  infection  of  intestinal  epithelial cells has been proposed [88]. Similarly, 
Thirabunyanon et al. found that a novel probiotic Bacillus subtilis NC11 strain has a protective  
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activity against Salmonella enteritidis infection of intestinal epithelial cells (unpublished data). Fayol-
Messaoudi  et  al.  [40]  showed  that  the  probiotic  Lactobacillus  plantarum  ACA-DC287  strain 
isolated  from  Greek  cheese  can  inhibit  the  adhesion  of  Salmonella  typhimurium  to  intestinal 
epithelium  cells.  When  mice  infected  with  S.  typhimurium  took  this  probiotic,  it  resulted  in  a 
decrease in the levels of Salmonella in the intestinal tissues and contents. Lactobacillus fermentum 
ACA-DC179 was found to exert a protective effect against S. typhimurium  infection in mice [89] 
while two Lactobacillus strains, LAP5 and LF33, showed significant antagonistic effects against S. 
typhimurium invasion of internal organs such as liver and spleen in mice that were fed the lactic acid 
bacteria  daily  for  7  consecutive  days  [90].  Similarly,  Chiu  et  al.  [41]  found  that  Pediococcus 
pentosaceus MP12 and Lactobacillus plantarum LAP6 are able to inhibit Salmonella invasion in 
mouse liver and spleen. In another study, mice pre-fed for 7 days with milk containing Lactobacillus 
casei (probiotic dahi) prior to challenging with Salmonella enteritidis showed increasing production 
of IL-2, IL-6 and IFN-gamma, whereas IL-4 decreased in splenic lymphocytes, indicating protection 
against S. enteritidis infection by enhancement of innate and adaptive immunity [91].   
 
 Escherichia coli 
  
Diarrheagenic E. coli is known to be the cause of various forms of diarrhoea and is classified 
into  six  categories,  namely  enteropathogenic  E.  coli  (EPEC),  enterotoxigenic  E.  coli  (ETEC), 
enterohemorrhagic  E.  coli  (EHEC),  enteroinvasive  E.  coli  (EIEC),  enteroaggregative  E.  coli 
(EAggEC)  and  diffusely  adherent  E.  coli  (DAEC)  [92-93].  Certain  strains  of  EHEC  are  highly 
infectious pathogens that produce one or more Shiga toxins which induce gastrointestinal diseases 
such  as  diarrhoea,  hemorrhagic  colitis  and  life-threatening  hemolytic  uremic syndrome (HUS) in 
humans [94-95]. It is known that outbreaks of EHEC with serotype O157:H7 continually occur 
worldwide and pose a serious global health threat [96]. EHEC likely evolved from an EPEC strain; 
this  enables  EHEC  to  produce  lesions  on  host  intestinal  epithelial  cells,  thus  reducing  intestinal 
epithelial  barrier  function  [97].  EAggEC  infection  is  associated  with  childhood  [98]  and  adult 
diarrhoea [99] such as travellers’ diarrhoea, pediatric diarrhoea and persistent diarrhoea [100]. These 
EAggEC strains have been observed in weaning foods, infant feeding bottles, milk and water [101]. 
Limited use of antibiotics for treating E. coli infection and alternative therapies such as application of 
probiotics are recommended. 
  Probiotic Lactobacillus acidophilus RY2 strain isolated from faeces of healthy infants can 
inhibit EAggEC adhesion to intestinal epithelial cells, thus preventing pathogenic colonisation and 
infection [102]. Similarly, Ostad et al. [103] concluded that the probiotic L. acidophilus in both live 
and  heat-inactivated  forms  isolated  from  neonatal  faeces  decreases  the  adhesion  of  E.  coli  to 
intestinal epithelial cells. Miyazaki et al. [93] demonstrated that a probiotic strain of Enterococcus 
faecium has bactericidal effects on EAggEC by inducing membrane damage and cell lysis. Protection 
of the tight junction of intestinal epithelial cells against EHEC-induced damage has been found via 
the activity of probiotic Bifidobacterium lactis 420 strain [104]. Mangell et al. [105] pre-fed rats 
with probiotic Lactobacillus plantarum 299v strain in drinking water and then challenged them with 
an E. coli-induced increase in intestinal permeability. The results showed that this probiotic strain can 
exert a protective effect. A comparison of probiotic feeding with Bifidobacterium thermacidophilum 
RBL71 for 7 days before and after infection with EHEC E. coli O157:H7 in mice was investigated.  
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The  effects  were  greater  in  the  pre-challenged  group  compared  to  the  after-treatment  group, 
resulting in increased feed intake and weight gain and lower faecal levels of E. coli O157:H7 [106].  
 
Listeria monocytogenes 
 
L. monocytogenes has been found to be a contaminant in various raw and processed foods 
such as beef, pork, sausages, milk, dairy products, vegetables and seafood products [107-108]. It 
causes listeriosis, a foodborne pathogenic illness that primarily infects pregnant women, newborns 
and  elderly  or  weakened  individuals  [109].  Listeria  has  also  been  implicated  as  the  cause  of 
septicemia, spontaneous abortion and even death of infected individuals [110]. The mortality rate of 
this illness may reach 20-30%, making it a serious public health menace [107]. L. monocytogenes is 
known  to  tolerate  environmental  stresses including variations in pH, temperature and osmolarity 
[111]. Because it can survive in foods for long periods of time, it has been implicated in outbreaks in 
meat and dairy products [112-113]. 
Infection by L. monocytogenes may translocate from the gastrointestinal tract to other organs 
such as liver, spleen, central nervous system and placenta [114]. Several biotherapeutic agents for L. 
monocytogenes infection have been investigated. De Waard et al. [115] demonstrated that rats fed 
Lactobacillus casei Shirota YIT9029 strain continuously for 3 days before being infected with L. 
monocytogenes show reduced levels of the pathogen in the faeces and several organs, i.e. stomach, 
caecum,  spleen  and  liver.  Corr  et  al.  [116]  observed  the  anti-infective  activity  of Lactobacillus 
salivarius UCC118, a strain of human origin that produces Abp118 bacteriocin which can protect 
against  L.  monocytogenes  infection  in  mice. In  another  study,  after  orally  feeding  Lactobacillus 
plantarum to mice continuously for 30 days and then challenging by intravenous infection with a 
clinical strain of L. monocytogenes, it was found that the administration of L. plantarum reduces pro-
inflammatory interleukin (IL-1 beta and IL-6) production, implicating the host protection against L. 
monocytogenes [117]. Similar results were found in mice treated with Lactobacillus delbrueckii var. 
bulgaricus UFV-H2b20 and challenged with L. monocytogenes. The mice were more resistant to this 
pathogenic infection, as registered by mortality rates and number of bacteria in spleen and liver. They 
also showed increasing production of inflammatory cytokines (interferon-gamma and tumor necrosis 
factor-alpha) and nitric oxide [118].   
 
Clostridium difficile and rotavirus 
 
Evaluation  of  potential  probiotics  for  their  ability  to  protect  against  infection  by  other 
intestinal pathogens has also been undertaken. Effective probiotic treatments of C. difficile infection 
which  causes  gastrointestinal  illness  have  been  proposed  [119-122].  Protection  against  rotavirus 
infection  which  is  a  leading  cause  of  gastroenteritis,  especially  in  young  children,  has  also been 
investigated [123-124].       
 
CONCLUSIONS 
 
Recently,  human  diseases  and  probiotic  bacteria  have  become  interrelated  fields  of 
investigation through the association with gastrointestinal infections from foodborne pathogens that 
are known to be a main cause of morbidity and mortality worldwide. Hence, many studies are now in 
progress on the applicability of probiotic bacteria as an alternative biotherapeutic treatment for, and  
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protection against, gastrointestinal pathogenic infections. Probiotic bacteria are derived from human 
microbiota; since they are of human origin, they may have key features as primary sources for human 
disease therapies. New sources which originate from fermented foods are also significant for both 
functional food development and alternative biotherapies. One important limitation is that only one 
kind  of  probiotic  bacteria  may  not  exert  protection  against  all  harmful  strains  that  cause 
gastrointestinal  pathogenic  infections.  Therefore,  effective  investigations  of  individual  strains  of 
probiotic  bacteria  and  also  of  new  formulations  that  combine  several  probiotic  activities  in 
challenging certain gastrointestinal pathogens
__in vitro, by cell culture, and in animal models as well 
as in humans as a final evaluation
__are necessary before a biotherapeutic application.  Biotherapy 
with  probiotic  bacteria  for  gastrointestinal  pathogenic  infections  may  modulate  functions  of  the 
microbiota and intestinal epithelium in the gastrointestinal tract, resulting in many documented action 
modes  such  as antimicrobial production, nutritional substrate competition, competitive exclusion, 
intestinal epithelial function, and immunomodulation. The present investigations of this alternative 
biotherapeutic application of probiotics to protection against gastrointestinal pathogenic infections 
may be of great importance for both present and future medicinal use. 
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